Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 8/20 | 0.39 |
| ▸ | MMP8 | P22894 | 6/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039661 | 0.94 | TRPA1 (0.40) | TRPA1ALDH1A1HPGDSMN1; SMN2RORC | |
| SCHEMBL4033850 | 0.93 | MAPT (0.39) | TRPA1ALDH1A1HPGDSMN1; SMN2RORC | |
| SCHEMBL4033378 | 0.89 | RORC (0.40) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4843267 | 0.88 | RORC (0.41) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4033168 | 0.87 | THRA (0.38) | TRPA1ALDH1A1HPGDSMN1; SMN2MMP8 | |
| SCHEMBL4841542 | 0.87 | RORC (0.42) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4039136 | 0.86 | RORC (0.41) | TRPA1RORC | |
| SCHEMBL4031790 | 0.86 | TRPA1 (0.46) | TRPA1ALDH1A1RORCMMP8MMP3 | |
| SCHEMBL4842217 | 0.85 | RORC (0.39) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4841404 | 0.85 | RORC (0.42) | TRPA1RORCMMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TRPA1 368/4885ALDH1A1 1819/4885HPGD 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.